(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 October 2021 (14.10.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/204998 A1

(51) International Patent Classification:
A61K 39/04 (2006.01) *A61P 11/00* (2006.01)
A61K 39/09 (2006.01) *A61P 25/28* (2006.01)
A61P 31/00 (2006.01) *A61P 37/00* (2006.01)
A61P 31/14 (2006.01) *C07K 16/06* (2006.01)
A61P 9/10 (2006.01) *C07K 16/00* (2006.01)

(21) International Application Number:
PCT/EP2021/059294

(22) International Filing Date:
09 April 2021 (09.04.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
20169203.5 10 April 2020 (10.04.2020) EP
20172424.2 30 April 2020 (30.04.2020) EP
20195313.0 09 September 2020 (09.09.2020) EP

(71) Applicant: **HEIDELBERG IMMUNOTHERAPEUTICS GMBH** [DE/DE]; Max-Jarecki-Strasse 21, 69115 Heidelberg (DE).

(72) Inventors: **ÜBELHART, Rudolf**; Schulstrasse 47, 69207 Sandhausen (DE). **SCHALLER, Torsten**; Bürgermeister-Weidemaier-Strasse 1A, 69181 Leimen (DE). **ARNDT, Michaela**; Dänischer Tisch 23a, 68219 Mannheim (DE).

(74) Agent: **VOSSIUS & PARTNER (NO 31)**; Patentanwälte Rechtsanwälte mbB, Siebertstrasse 3, 81675 München (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: NATURAL ANTIBODIES IN PROPHYLAXIS AND THERAPY

(57) Abstract: Described is a human or humanized natural IgM and/or IgA antibody recognizing oxidized phospholipids and/or oxidation-specific epitopes for use in a method of treating or preventing a disorder or a disease associated with/related to/caused by a natural IgM/IgA antibody deficiency (NAD) in a subject. Moreover, described is a vaccine comprising a compound that induces the generation of natural IgM and/or IgA antibodies for use in a method of reducing or preventing the clinical signs or disease associated with/related to/caused by natural IgM/IgA antibody deficiency (NAD) in a subject, wherein said vaccine comprises a pharmaceutically acceptable carrier or excipient. Further, described is such a vaccine for use in a method of reducing or preventing the clinical signs or disease associated with/related to/caused by natural IgM/IgA antibody deficiency (NAD) in a subject, wherein said compound induces human natural IgM and/or IgA antibody recognizing oxidized phospholipids and/or oxidation-specific epitopes.

WO 2021/204998 A1